Literature DB >> 10721019

Are QALYs an appropriate measure for valuing morbidity in acute diseases?

M V Bala1, G A Zarkin.   

Abstract

In this paper, we examine the problems associated with using quality adjusted life years (QALYs) as the measure of effectiveness to evaluate interventions for acute conditions. We illustrate the way in which using commonly accepted benchmarks for costs per QALY, in order to adopt interventions for acute conditions, might result in decisions that are not consistent with maximizing net societal benefit. We suggest that an alternate methodology, such as willingness to pay, may be more appropriate to make allocation decisions for acute conditions. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 10721019     DOI: 10.1002/(sici)1099-1050(200003)9:2<177::aid-hec497>3.0.co;2-2

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  15 in total

1.  Empirical validation of patient versus population preferences in calculating QALYs.

Authors:  Eva-Julia Weyler; Afschin Gandjour
Journal:  Health Serv Res       Date:  2011-04-21       Impact factor: 3.402

2.  The measurement of contingent valuation for health economics.

Authors:  Ahmed M Bayoumi
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

3.  Why not real economics?

Authors:  F Reed Johnson
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

Review 4.  Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data.

Authors:  Meenakshi Bewtra; F Reed Johnson
Journal:  Patient       Date:  2013       Impact factor: 3.883

5.  Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients.

Authors:  A D Griffin; A S Perry; D M Fleming
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Over-the-scope clips are cost-effective in recurrent peptic ulcer bleeding.

Authors:  Armin Kuellmer; Juliane Behn; Benjamin Meier; Andreas Wannhoff; Dominik Bettinger; Robert Thimme; Karel Caca; Arthur Schmidt
Journal:  United European Gastroenterol J       Date:  2019-09-25       Impact factor: 4.623

7.  Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding.

Authors:  Alan N Barkun; Viviane Adam; Joseph J Y Sung; Ernst J Kuipers; Joachim Mössner; Dennis Jensen; Robert Stuart; James Y Lau; Emma Nauclér; Jan Kilhamn; Helena Granstedt; Bengt Liljas; Tore Lind
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  Economic evaluation of dexmedetomidine relative to midazolam for sedation in the intensive care unit.

Authors:  Jean Lachaine; Catherine Beauchemin
Journal:  Can J Hosp Pharm       Date:  2012-03

9.  Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT.

Authors:  Jan E Clarkson; Nigel B Pitts; Beatriz Goulao; Dwayne Boyers; Craig R Ramsay; Ruth Floate; Hazel J Braid; Patrick A Fee; Fiona S Ord; Helen V Worthington; Marjon van der Pol; Linda Young; Ruth Freeman; Jill Gouick; Gerald M Humphris; Fiona E Mitchell; Alison M McDonald; John Dt Norrie; Kirsty Sim; Gail Douglas; David Ricketts
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.014

Review 10.  The impact of economic evaluation on quality management in spine surgery.

Authors:  Norbert Boos
Journal:  Eur Spine J       Date:  2009-04-01       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.